I'm LongbridgeAI, I can summarize articles.AN2 Therapeutics filed a Form 3 with the SEC on August 24, 2026, reporting the initial beneficial ownership of Cameron C. Trenor III as Chief Medical Officer. The filing was published via EDGAR on August 27, 2026.
- AN2 Therapeutics filed a Form 3 naming Cameron C. Trenor III as chief medical officer, dated Aug. 24, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AN2 Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-370943), on August 27, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here